Private equity firms see considerable profits in healthcare, often at the expense of patients and families. Profit is a crucial driving focus of many businesses. Although private equity investment in health care could lead to improvement by injecting needed capital, a pressing concern is that many private equity firms often operate on the model of buying and quickly selling for a substantial profit within three years.

Healthcare is the problem of our country, and if we don’t fix it, it will break the bank, our health, or both. It deserves the world’s best and brightest minds working on fixing it. But how we go about fixing healthcare matters. The strategic common denominator across big tech ventures into healthcare is that they are not primarily solving what healthcare needs. They are mainly solving how to make money with their respective core business, not helping customers.

(CBS News)Employers are using a new strategy to deal with the high cost of drugs prescribed to treat conditions such as arthritis, psoriasis, cancer, and hemophilia. They are tapping into dollars provided through programs they have previously criticized: patient financial assistance initiatives set up by drugmakers, which some benefit managers have complained encourage patients to stay on expensive brand-name drugs when less expensive options might be available. Patients are, of course, caught in the middle.

ALS is a fatal neurodegenerative condition that affects chewing, talking, and walking, progresses to paralysis, and culminates in respiratory failure, typically within three to five years. An estimated 30,000 Americans live with ALS, sometimes called Lou Gehrig’s disease. On Sept. 29, the Food and Drug Administration approved Relyvrio from Amylyx Pharmaceuticals. It’s the first ALS medication to be approved in five years and only one of three currently prescribed to patients to slow the progression of the disease, but should it have been approved?